Equities researchers at Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research note issued to investors on Wednesday, The Fly reports. The brokerage set an “outperform” rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on REGN. Leerink Swann reissued an “outperform” rating and set a $573.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 22nd. Raymond James Financial, Inc. restated an “outperform” rating and set a $547.00 price objective (up from $475.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. BMO Capital Markets restated a “market perform” rating and set a $484.00 price objective (up from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Bank of America Corporation restated a “buy” rating and set a $593.00 price objective (up from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $488.23.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.85% during trading on Wednesday, hitting $468.54. The stock had a trading volume of 383,199 shares. The stock has a market cap of $49.68 billion, a price-to-earnings ratio of 47.00 and a beta of 1.66. The stock’s 50-day moving average price is $493.07 and its 200 day moving average price is $429.52. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same period in the prior year, the firm earned $2.82 earnings per share. Regeneron Pharmaceuticals’s revenue was up 21.2% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals will post $14.84 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Research Coverage Started at Evercore ISI” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/16/regeneron-pharmaceuticals-inc-regn-research-coverage-started-at-evercore-isi.html.

In related news, Chairman P Roy Vagelos sold 9,295 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $458.14, for a total transaction of $4,258,411.30. Following the completion of the transaction, the chairman now directly owns 414,156 shares in the company, valued at approximately $189,741,429.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Neil Stahl sold 2,812 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $479.49, for a total transaction of $1,348,325.88. Following the transaction, the executive vice president now owns 28,477 shares of the company’s stock, valued at $13,654,436.73. The disclosure for this sale can be found here. Insiders sold a total of 56,922 shares of company stock valued at $27,383,105 over the last 90 days. Corporate insiders own 10.40% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its position in Regeneron Pharmaceuticals by 55.0% in the first quarter. Bank of Montreal Can now owns 50,819 shares of the biopharmaceutical company’s stock worth $19,693,000 after buying an additional 18,030 shares in the last quarter. Alpha Windward LLC boosted its position in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the period. Atria Investments LLC boosted its position in shares of Regeneron Pharmaceuticals by 12.5% in the first quarter. Atria Investments LLC now owns 1,082 shares of the biopharmaceutical company’s stock valued at $419,000 after buying an additional 120 shares during the period. Hartwell J M Limited Partnership acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $401,000. Finally, Capital Impact Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 57.7% in the first quarter. Capital Impact Advisors LLC now owns 5,945 shares of the biopharmaceutical company’s stock valued at $2,304,000 after buying an additional 2,175 shares during the period. Institutional investors and hedge funds own 67.16% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.